Q1 2024 EPS Estimates for Henry Schein, Inc. Lowered by Zacks Research (NASDAQ:HSIC)

Henry Schein, Inc. (NASDAQ:HSIC) – Research analysts at Zacks Research decreased their Q1 2024 EPS estimates for shares of Henry Schein in a research note issued on Wednesday, May 1st. Zacks Research analyst U. Biswas now expects that the company will post earnings of $0.99 per share for the quarter, down from their prior estimate of $1.00. The consensus estimate for Henry Schein’s current full-year earnings is $5.07 per share. Zacks Research also issued estimates for Henry Schein’s Q4 2024 earnings at $1.42 EPS, FY2024 earnings at $5.05 EPS, Q1 2026 earnings at $1.46 EPS and FY2026 earnings at $5.99 EPS.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, February 27th. The company reported $0.66 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.04). Henry Schein had a net margin of 3.37% and a return on equity of 14.03%. The company had revenue of $3.02 billion during the quarter, compared to the consensus estimate of $3 billion. During the same quarter in the prior year, the firm posted $1.21 earnings per share. The business’s revenue was down 10.5% on a year-over-year basis.

HSIC has been the topic of several other reports. Piper Sandler upped their price target on shares of Henry Schein from $78.00 to $86.00 and gave the company an “overweight” rating in a report on Monday, February 26th. Jefferies Financial Group boosted their price objective on shares of Henry Schein from $74.00 to $81.00 and gave the company a “hold” rating in a research report on Wednesday, March 6th. Evercore ISI boosted their price objective on shares of Henry Schein from $79.00 to $83.00 and gave the company an “in-line” rating in a research report on Wednesday, February 28th. Leerink Partnrs reissued a “market perform” rating on shares of Henry Schein in a research report on Monday, February 26th. Finally, SVB Leerink started coverage on shares of Henry Schein in a research report on Monday, February 26th. They issued a “market perform” rating and a $78.00 price target for the company. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $81.09.

Henry Schein Stock Performance

Henry Schein stock opened at $67.78 on Friday. The company’s 50-day moving average price is $73.46 and its 200-day moving average price is $72.30. Henry Schein has a twelve month low of $60.01 and a twelve month high of $82.63. The company has a quick ratio of 1.00, a current ratio of 1.67 and a debt-to-equity ratio of 0.45. The company has a market cap of $8.71 billion, a PE ratio of 21.52, a price-to-earnings-growth ratio of 1.70 and a beta of 0.87.

Hedge Funds Weigh In On Henry Schein

Several hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of Henry Schein by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 15,171,464 shares of the company’s stock worth $1,148,632,000 after buying an additional 161,891 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Henry Schein by 1.1% during the third quarter. JPMorgan Chase & Co. now owns 4,766,305 shares of the company’s stock valued at $353,898,000 after acquiring an additional 53,506 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of Henry Schein by 7.3% in the third quarter. American Century Companies Inc. now owns 4,719,088 shares of the company’s stock valued at $350,392,000 after purchasing an additional 322,649 shares in the last quarter. Boston Partners grew its holdings in shares of Henry Schein by 144.1% in the fourth quarter. Boston Partners now owns 2,637,429 shares of the company’s stock valued at $199,393,000 after purchasing an additional 1,556,831 shares in the last quarter. Finally, Fiduciary Management Inc. WI grew its holdings in shares of Henry Schein by 17.1% in the fourth quarter. Fiduciary Management Inc. WI now owns 2,284,337 shares of the company’s stock valued at $172,947,000 after purchasing an additional 333,855 shares in the last quarter. 96.62% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Henry Schein

In related news, CEO Bradford C. Connett sold 6,430 shares of the stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total transaction of $477,620.40. Following the sale, the chief executive officer now directly owns 73,108 shares of the company’s stock, valued at $5,430,462.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Henry Schein news, Vice Chairman James P. Breslawski sold 2,907 shares of the stock in a transaction on Monday, March 18th. The shares were sold at an average price of $74.37, for a total transaction of $216,193.59. Following the transaction, the insider now directly owns 209,562 shares of the company’s stock, valued at $15,585,125.94. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Bradford C. Connett sold 6,430 shares of the stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total transaction of $477,620.40. Following the transaction, the chief executive officer now directly owns 73,108 shares in the company, valued at $5,430,462.24. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.